Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11380285 | 0.95 | KDM4E (0.58) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL1072576 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2SRC | |
| SCHEMBL4655558 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| SCHEMBL1771343 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| SCHEMBL9301841 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| Hydrochloric Acid SCHEMBL4652877 | 0.83 | KDM4E (0.47) | KDM4EENPP2 | |
| SCHEMBL14186117 | 0.81 | ENPP2 (0.46) | KDM4EENPP2 | |
| SCHEMBL9945908 | 0.80 | KDM4E (0.43) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL29700460 | 0.80 | MGLL (0.47) | KDM4E | |
| SCHEMBL21854599 | 0.80 | MGLL (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388783-A | Molecularly imprinted covalent organic framework composite material based on acid-induced color, preparation method and application thereof | 浙江树人学院 | 2024-07-26 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-119242161-A | Preparation method of plastic runway glue solution and plastic runway | 湖北金五环体育设施有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118852563-A | Hydrogen bond induced hierarchical pore covalent organic framework material and assembly method and application thereof | 浙江工业大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-118356686-A | Preparation method of visualized solid-phase extraction column based on acid-induced color molecular imprinting covalent organic framework composite material | 浙江树人学院 | 2024-07-19 | — | — | CN | disclosed |
| CN-117534807-B | Boric acid functionalized covalent organic framework material and preparation method and application thereof | 河南大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-117534807-A | Boric acid functionalized covalent organic framework material and preparation method and application thereof | 河南大学 | 2024-02-09 | — | — | CN | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4112606-A1 | AROMATIC COMPOUND AND USE THEREOF IN PREPARING ANTINEOPLASTIC DRUGS | Shanghai Zheye Biotechnology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| EP-2064192-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Discovery, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1588173-B1 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | NOVO NORDISK AS (DK) | 2008-11-26 | — | — | EP | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | TYR, MAPT, DDC | KDM4E 2335/4885PTGS2 4651/4885RAB9A 1573/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | KDM4E 1589/4885PTGS2 123/4885RAB9A 4705/4885 |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | KDM4E 2802/4885PTGS2 2058/4885RAB9A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.